STC 1010
Alternative Names: STC-1010Latest Information Update: 28 Sep 2025
At a glance
- Originator Brenus Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Tumour cell vaccines
- Mechanism of Action Immunostimulants
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Colorectal cancer
- No development reported Gastrointestinal cancer; Pancreatic cancer
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in France (Parenteral)
- 28 Sep 2025 No recent reports of development identified for preclinical development in Pancreatic-cancer in France (Parenteral)
- 29 Jul 2025 Phase-I/II clinical trials in Colorectal cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, First-line therapy) in France (Parenteral) (NCT06934538)
